Abstract 1463P
Background
Chemotherapy in combination with anti-PD-1/PD-L1 antibodies (chemoimmunotherapy) has become the standard treatment for advanced non-small cell lung cancer (NSCLC). Our previous studies highlighted that low baseline concentrations of IL-6 in plasma specimens or tumor tissues responded better to anti-PD-1/PD-L1 immunotherapy alone. However, the role of baseline IL-6 levels in predicting responses to chemoimmunotherapy and the development of resistance to chemoimmunotherapy has not been fully understood yet.
Methods
To confirm the predictive value of IL-6 in the baseline plasma, we conducted an enzyme-linked immunosorbent assay (ELISA) in a group of 123 advanced NSCLC patients who received chemoimmunotherapy. Next, we evaluated the role of IL-6 in chemoimmunotherapy resistance and the underlying mechanisms in mouse models of both lung adenocarcinoma and lung squamous cell carcinoma.
Results
Based on our cohort of 123 NSCLC patients, we found that patients with progressive disease had a higher baseline level of IL-6 in their plasma. Additionally, the potential predictive value of the baseline level of IL-6 in plasma samples for responses was confirmed with area under curve (AUC) up to 0.677. Patients with a low baseline concentration of IL-6 also had a longer progression-free survival and overall survival, with a cut-off value of 7.002 obtained from receiver operating characteristic curve (ROC). Meanwhile, univariate and multivariate Cox regression analyses revealed that baseline IL-6 level in plasma samples was an independent prognostic predictor. Further experiments in mouse models showed that overexpression of IL-6 weakened the anti-tumor effects of immunotherapy in combination with chemotherapy. Immunohistochemical studies also revealed that CD8+ T cells decreased while M2 macrophages, regulating T cells, and myeloid-derived suppressor cells infiltration increased in the IL-6 overexpressing group.
Conclusions
Our study highlights the potential of baseline IL-6 levels as a useful predictive biomarker for chemoimmunotherapy in NSCLC. IL-6 promotes an immunosuppressive tumor microenvironment, suggesting that targeting IL-6 could be a promising approach for cancer treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1390P - Real-world characteristics, treatment patterns and outcomes of patients with advanced HER2/ERBB2-mutant non-small cell lung cancer (NSCLC) in France and Germany
Presenter: Petros Christopoulos
Session: Poster session 20
1391P - Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
Presenter: Oscar Jose Juan Vidal
Session: Poster session 20
1392P - Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP)
Presenter: Karlijn Verkerk
Session: Poster session 20
1393P - Characteristics of MET gene and its relationship with TMB/MMR genes in Chinese NSCLC population
Presenter: Hong Yi Zhang
Session: Poster session 20
1394P - Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations
Presenter: Urska Janzic
Session: Poster session 20
1396P - HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
Presenter: Didier Debieuvre
Session: Poster session 20
1397P - Prevalence, molecular characterization, and prognosis of MET–overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort
Presenter: Jair Bar
Session: Poster session 20
1398P - Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)
Presenter: Sophie Ernst
Session: Poster session 20
1399P - Tumor-immune microenvironment analysis of de novo and acquired KRAS-mutated non-small cell lung cancer
Presenter: Joshua Reuss
Session: Poster session 20
1400P - Real-world effectiveness and safety of sotorasib in patients with KRAS G12C mutated metastatic non-small cell lung cancer (NSCLC): Results of the IFCT-2102 Lung KG12Ci study
Presenter: Marie Wislez
Session: Poster session 20